Evaluation of the Effects of Caffeine, Via the ACE2 Receptor, on Clinical Severity of COVID-19 Disease


About this study

The purpose of this study is to assess levels of caffeine intake among patients who tested positive for COVID-19 infection and compare that to disease severity.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Males and females 18 years of age and above at the time of informed consent
  • Tested positive for COVID-19 at a Mayo Clinic Florida site
  • At least one prior clinic encounter at Mayo Clinic for chart review purposes.

Exclusion Criteria:

  • No prior clinical encounters at Mayo Clinic.



Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Pablo Castillo, M.D.

Open for enrollment

Contact information:

Pablo Castillo M.D.


More information


Publications are currently not available

Mayo Clinic Footer